JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB265193

Human PRKAR1B knockout HeLa cell line

Be the first to review this product! Submit a review

|

(0 Publication)

PRKAR1B KO cell line available to order. KO validated. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp deletion in exon 2. To order both knockout and wild-type control cells: select '2 x 1000000 Cells/vial'. To order only knockout cells: select '1000000 Cells/vial'.
1 Images
Sanger Sequencing - Human PRKAR1B knockout HeLa cell line (AB265193)
  • Sanger seq

Unknown

Sanger Sequencing - Human PRKAR1B knockout HeLa cell line (AB265193)

Homozygous : 1 bp deletion in exon 2.

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp deletion in exon 2

Disease

Adenocarcinoma

Product details

We will provide viable cells that proliferate on revival.

Western blot data indicates that the CRISPR gene edit may have resulted in a truncation of the protein of interest. Please see data images.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab265193-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab255928 Human wild-type HeLa cell line", "number":"AB265193-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab265193 Human PRKAR1B knockout HeLa cell line", "number":"AB265193-CMP01" } ] }, "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab265193-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265193 Human PRKAR1B knockout HeLa cell line", "number":"AB265193-CMP01" }, { "size":"1 x 1000000 Cells/vial", "name":"ab255928 Human wild-type HeLa cell line", "number":"AB265193-CMP02" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab265193-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265193 Human PRKAR1B knockout HeLa cell line", "number":"AB265193-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab265193-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265193 Human PRKAR1B knockout HeLa cell line", "number":"AB265193-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
PRKAR1B
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Zygosity
Homozygous
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

PRKAR1B also known as the regulatory subunit type I beta of protein kinase A (PKA) plays an important role in the regulation of cAMP-dependent PKA activity. This protein has a molecular mass of approximately 44 kDa. It binds to the catalytic subunit of PKA inhibiting its activity until cAMP binds which then triggers a conformational change and release of the active catalytic subunit. PRKAR1B is expressed in various tissues with notable abundance in the brain highlighting its significance in neuronal signaling.
Biological function summary

PRKAR1B functions as part of the PKA holoenzyme complex which includes both regulatory and catalytic subunits. The regulatory subunit PRKAR1B directly controls when and where PKA catalytic activity occurs influencing multiple cellular responses. This protein modulates processes like glycogen lipid and protein metabolism by contributing to the precise regulation of cAMP signaling pathways. Its activity affects a range of fundamental cellular functions indicative of its presence in diverse tissues.

Pathways

PRKAR1B is intricately involved in the cAMP signaling pathway and the MAPK/ERK pathway. The cAMP pathway is important for transferring the signals of many hormones and neurotransmitters where PRKAR1B regulates transient PKA activation. In the MAPK/ERK pathway PRKAR1B indirectly influences cellular growth and differentiation by modulating secondary messengers. Proteins such as the catalytic subunits of PKA and CREB a transcription factor interact with PRKAR1B illustrating its central role in cellular responses to external signals.

PRKAR1B has been associated with neurodegenerative diseases like Alzheimer's and mood disorders such as major depressive disorder. Altered regulation of the cAMP signaling pathway influenced by PRKAR1B affects neuronal survival and function potentially leading to neurodegeneration. Additionally imbalances in PRKAR1B-mediated pathways can contribute to mood disorders. Proteins such as the catalytic subunits of PKA and BDNF (brain-derived neurotrophic factor) interact with PRKAR1B in these contexts indicating its potential as a therapeutic target.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com